Bausch and Lomb CEO: No Plans to Resuscitate Sale Process in 2025
After exploring a potential sale, Bausch and Lomb (BLCO) has stated that it will not pursue a transaction at this time. CEO Brent Saunders expressed skepticism about restarting the deal process in 2025, citing the company's ambitious growth plans.
Saunders acknowledges that the company's product pipeline, including advancements in contact lenses, dry eye solutions, and surgical products, may have been undervalued by potential buyers. He remains confident that the company can drive a higher valuation in the future.
Bausch and Lomb's recent financial performance supports Saunders' optimism. The company reported strong fourth quarter sales, driven by growth in its vision care segment. It forecasts sales within a range of $4.95 billion to $5.05 billion for the full year.
The company's focus for 2025 and beyond is on executing its ambitious growth plans and maximizing operational efficiency. Saunders believes that these initiatives will enhance the company's value and position it for future opportunities.
Key Highlights:
* Bausch and Lomb has decided against pursuing a sale at this time.
* CEO Brent Saunders is confident that the company can drive a higher valuation in the future.
* The company's recent financial performance and product pipeline support Saunders' optimism.
* Bausch and Lomb remains focused on executing its growth plans and delivering exceptional results.